1. Home
  2. STTK vs TG Comparison

STTK vs TG Comparison

Compare STTK & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • TG
  • Stock Information
  • Founded
  • STTK 2016
  • TG 1988
  • Country
  • STTK United States
  • TG United States
  • Employees
  • STTK N/A
  • TG N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • TG Metal Fabrications
  • Sector
  • STTK Health Care
  • TG Industrials
  • Exchange
  • STTK Nasdaq
  • TG Nasdaq
  • Market Cap
  • STTK 37.6M
  • TG 301.0M
  • IPO Year
  • STTK 2020
  • TG 1989
  • Fundamental
  • Price
  • STTK $0.82
  • TG $8.92
  • Analyst Decision
  • STTK Hold
  • TG
  • Analyst Count
  • STTK 4
  • TG 0
  • Target Price
  • STTK $3.00
  • TG N/A
  • AVG Volume (30 Days)
  • STTK 396.2K
  • TG 74.5K
  • Earning Date
  • STTK 07-31-2025
  • TG 08-06-2025
  • Dividend Yield
  • STTK N/A
  • TG N/A
  • EPS Growth
  • STTK N/A
  • TG N/A
  • EPS
  • STTK N/A
  • TG N/A
  • Revenue
  • STTK $4,606,000.00
  • TG $617,839,000.00
  • Revenue This Year
  • STTK N/A
  • TG N/A
  • Revenue Next Year
  • STTK N/A
  • TG N/A
  • P/E Ratio
  • STTK N/A
  • TG N/A
  • Revenue Growth
  • STTK 69.65
  • TG 17.42
  • 52 Week Low
  • STTK $0.69
  • TG $4.58
  • 52 Week High
  • STTK $4.99
  • TG $9.22
  • Technical
  • Relative Strength Index (RSI)
  • STTK 37.21
  • TG 59.32
  • Support Level
  • STTK $0.77
  • TG $8.64
  • Resistance Level
  • STTK $1.14
  • TG $8.98
  • Average True Range (ATR)
  • STTK 0.09
  • TG 0.26
  • MACD
  • STTK -0.03
  • TG -0.00
  • Stochastic Oscillator
  • STTK 9.88
  • TG 64.83

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: